This is a summary of the European public assessment report (EPAR) for Ibandronic acid Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Ibandronic acid Accord. For practical information about using Ibandronic acid Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Ibandronic acid is indicated in adults for - Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. - Treatment of tumour induced hypercalcaemia with or without metastases. Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1). A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.
Therapeutic Area (MeSH)
ATC Code
M05BA06
ATC Item
ibandronic acid
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| ibandronic acid | N/A | 伊班膦酸钠 |
EMA Name
Ibandronic acid Accord
Medicine Name
Ibandronic acid Accord
Aliases
N/ANo risk management plan link.
